Jennifer Plichta

Overview:

Dr. Jennifer Plichta is an Associate Professor of Surgery & Population Health Sciences at Duke University. She serves as the Director of the Breast Risk Assessment Clinic in the Duke Cancer Institute, where she cares for patients with breast cancer, benign breast problems, and those with an increased risk of breast cancer. Her clinical interests include establishing routine breast cancer risk assessment for women and creating personalized management strategies for those found to be “high risk”.

 

Dr. Plichta’s research focuses of identifying and managing women with risk factors for breast cancer, including those with genetic mutations, such as BRCA, those with abnormal breast biopsies, and those with a family history of breast cancer. She is also studying metastatic breast cancer and how breast cancer staging can be used to improve patient care and education. 

 

However, her dedication to breast cancer extends beyond her clinical and research interests. She also enjoys educating the community about breast cancer and helping to raise money for breast cancer research and education. She is the creator and primary coordinator of Duke’s free, annual breast education day for the community, “What’s best for breasts?”.

Positions:

Associate Professor of Surgery

Surgical Oncology
School of Medicine

Associate Professor in Population Health Sciences

Population Health Sciences
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.A. 2002

Depauw University

M.D. 2008

Indiana University, School of Medicine

M.S. 2012

Loyola University Medical Center

General Surgery Resident, Surgery

Loyola University Medical Center

Breast Surgery Fellowship, Surgery

Brigham and Women's Hospital

Breast Surgery Fellowship, Surgery

Dana-Farber Cancer Institute

Breast Surgery Fellowship, Surgery

Massachusetts General Hospital

Grants:

Genetic testing for women with high-risk breast lesions

Awarded By
The Color Foundation
Role
Principal Investigator
Start Date
End Date

Combined breast MRI/biomarker strategies to identify aggressive biology

Administered By
Surgical Oncology
Awarded By
City of Hope
Role
Principal Investigator
Start Date
End Date

Publications:

The art of peer review: Guidelines to become a credible and constructive peer reviewer.

Peer review is a learned skill set that requires knowledge of study design, review construct, ethical considerations, and general expertise in a field of study. Participating in peer review is a rewarding and valuable experience in which all academic physicians are encouraged to partake. However, formal training opportunities in peer review are limited. In 2021, the Association of Women Surgeons and the journal Surgery collaborated to develop a Peer Review Academy. This academy is a 1-year longitudinal course that offers a select group of young women surgical trainees across all specialties a curriculum of monthly lectures and multiple formal mentored peer review opportunities to assist them in developing the foundation necessary to transition to independent peer review. The trainees and faculty mentors participating in the Association of Women Surgeons-Surgery Peer Review Academy compiled a summary of best peer review practices, which is intended to outline the elements of the skill set necessary to become a proficient peer reviewer.
Authors
Weaver, ML; Sundland, R; Adams, AM; Faria, I; Feldman, HA; Gudmundsdottir, H; Marmor, H; Miles, V; Ochoa, B; Ruff, SM; Tonelli, C; Altieri, MS; Cannada, L; Dewan, K; Etkin, Y; Marmor, R; Plichta, JK; Reyna, C; Tatebe, L; Drudi, LM; Hicks, CW
MLA Citation
Weaver, M. Libby, et al. “The art of peer review: Guidelines to become a credible and constructive peer reviewer.Semin Vasc Surg, vol. 35, no. 4, Dec. 2022, pp. 470–78. Pubmed, doi:10.1053/j.semvascsurg.2022.10.002.
URI
https://scholars.duke.edu/individual/pub1557709
PMID
36414364
Source
pubmed
Published In
Seminars in Vascular Surgery
Volume
35
Published Date
Start Page
470
End Page
478
DOI
10.1053/j.semvascsurg.2022.10.002

Implications of missing data on reported breast cancer mortality.

BACKGROUND: National cancer registries are valuable tools to analyze patterns of care and clinical outcomes; yet, missing data may impact the accuracy and generalizability of these data. We sought to evaluate the association between missing data and overall survival (OS). METHODS: Using the NCDB (National Cancer Database) and SEER (Surveillance, Epidemiology, End Results Program), we assessed data missingness among patients diagnosed with invasive breast cancer from 2010 to 2014. Key variables included demographic (age, race, ethnicity, insurance, education, income), tumor (grade, ER, PR, HER2, TNM stages), and treatment (surgery in both databases; chemotherapy and radiation in NCDB). OS was compared between those with and without missing data using Cox proportional hazards models. RESULTS: Overall, 775,996 patients in the NCDB and 263,016 in SEER were identified; missing at least 1 key variable occurred for 29% and 13%, respectively. Of those, the overwhelming majority (NCDB 80%; SEER 88%) were missing tumor variables. When compared to patients with complete data, missingness was associated with a greater risk of death: NCDB HR 1.23 (99% CI 1.21-1.25) and SEER HR 2.11 (99% CI 2.05-2.18). Patients with complete tumor data had higher unadjusted OS estimates than that of the entire sample: NCDB 82.7% vs 81.8% and SEER 83.5% vs 81.7% for 5-year OS. CONCLUSIONS: Missingness of select variables is not uncommon within large national cancer registries and is associated with a worse OS. Exclusion of patients with missing variables may introduce unintended bias into analyses and result in findings that underestimate breast cancer mortality.
Authors
Plichta, JK; Rushing, CN; Lewis, HC; Rooney, MM; Blazer, DG; Thomas, SM; Hwang, ES; Greenup, RA
MLA Citation
Plichta, Jennifer K., et al. “Implications of missing data on reported breast cancer mortality.Breast Cancer Res Treat, Nov. 2022. Pubmed, doi:10.1007/s10549-022-06764-4.
URI
https://scholars.duke.edu/individual/pub1555187
PMID
36334190
Source
pubmed
Published In
Breast Cancer Res Treat
Published Date
DOI
10.1007/s10549-022-06764-4

ASO Visual Abstract: The Influence of BMI on the Histopathology and Outcomes of Patients with a Diagnosis of Atypical Breast Lesions.

Authors
Miller, KN; Thomas, SM; Sergesketter, AR; Rosenberger, LH; DiLalla, G; van den Bruele, AB; Hwang, ES; Plichta, JK
MLA Citation
Miller, Krislyn N., et al. “ASO Visual Abstract: The Influence of BMI on the Histopathology and Outcomes of Patients with a Diagnosis of Atypical Breast Lesions.Ann Surg Oncol, vol. 29, no. 10, Oct. 2022, p. 6495. Pubmed, doi:10.1245/s10434-022-12445-9.
URI
https://scholars.duke.edu/individual/pub1533583
PMID
36002701
Source
pubmed
Published In
Annals of Surgical Oncology
Volume
29
Published Date
Start Page
6495
DOI
10.1245/s10434-022-12445-9

Flame Burns

Authors
Plichta, JK; Mosier, MJ
MLA Citation
Plichta, Jennifer K., and Michael J. Mosier. “Flame Burns.” Encyclopedia of Trauma Care, Springer Berlin Heidelberg, 2015, pp. 629–36. Crossref, doi:10.1007/978-3-642-29613-0_329.
URI
https://scholars.duke.edu/individual/pub1430871
Source
crossref
Published Date
Start Page
629
End Page
636
DOI
10.1007/978-3-642-29613-0_329

Call for action: expanding global access to hereditary cancer genetic testing.

Authors
Bychkovsky, B; Rana, HQ; Ademuyiwa, F; Plichta, J; Anderson, K; Nogueira-Rodrigues, A; Santa-Maria, CA; Coffman, LG; Marquez, C; Das, A; Taghian, A; Koeller, DR; Sandoval, RL; Park, BH; Dizon, DS
MLA Citation
Bychkovsky, Brittany, et al. “Call for action: expanding global access to hereditary cancer genetic testing.Lancet Oncol, vol. 23, no. 9, Sept. 2022, pp. 1124–26. Pubmed, doi:10.1016/S1470-2045(22)00378-3.
URI
https://scholars.duke.edu/individual/pub1535054
PMID
36055301
Source
pubmed
Published In
Lancet Oncol
Volume
23
Published Date
Start Page
1124
End Page
1126
DOI
10.1016/S1470-2045(22)00378-3